Tolerance and sensitization to chronic escalating dose heroin following extended withdrawal in Fischer rats: Possible role of mu-opioid receptors

Psychopharmacology

Volumn 225, Issue 1, 2013, Pages 127-140

  Seip Cammack, Katharine M ^a   Reed, Brian ^a   Zhang, Yong ^a   Ho, Ann ^a   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Addiction; Autoradiography; Behavior; Conditioning; Locomotor activity; Opiate; Opioid receptor; Rat; Sensitization; Tolerance

Indexed keywords

DIAMORPHINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); MU OPIATE RECEPTOR; SODIUM CHLORIDE; SULFUR 35; TRITIUM;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CAGE; CAUDATE NUCLEUS; CINGULATE GYRUS; CONDITIONING; CONTROLLED STUDY; DOSE RESPONSE; DRUG REEXPOSURE; DRUG SENSITIZATION; DRUG TOLERANCE; DRUG WITHDRAWAL; FRONTAL CORTEX; HEROIN DEPENDENCE; LOCOMOTION; MALE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; RAT; RECEPTOR DENSITY; STEREOTYPY; STUPOR; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

ANIMALS; BEHAVIOR, ADDICTIVE; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; HEROIN; HEROIN DEPENDENCE; MALE; MOTOR ACTIVITY; RATS; RATS, INBRED F344; RECEPTORS, OPIOID, MU; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84872280711     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2801-2     Document Type: Article

References (94)

1. Babbini M, Gaiardi M, Bartoletti M (1975) Persistence of chronic morphine effects upon activity in rats 8 months after ceasing the treatment. Neuropharmacology 14:611-614
2. Badiani A, Oates MM, Robinson TE (2000) Modulation of morphine sensitization in the rat by contextual stimuli. Psychopharmacology (Berl) 151:273-282
3. Bailey CP, Connor M (2005) Opioids: cellular mechanisms of tolerance and physical dependence. Curr Opin Pharmacol 5:60-68
4. Bailey A, Gianotti R, Ho A, Kreek MJ (2005) Persistent upregulation of mu-opioid, but not adenosine, receptors in brains of long-term withdrawn escalating dose "binge" cocaine-treated rats. Synapse 57:160-166
5. Bailey A, Metaxas A, Al-Hasani R, Keyworth HL, Forster DM, Kitchen I (2010) Mouse strain differences in locomotor, sensitisation and rewarding effect of heroin; association with alterations in MOP-r activation and dopamine transporter binding. Eur J Neurosci 31:742-753
6. Bals-Kubik R, Ableitner A, Herz A, Shippenberg TS (1993) Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther 264:489-495
7. Bartoletti M, Gaiardi M, Gubellini G, Bacchi A, Babbini M (1983) Long-term sensitization to the excitatory effects of morphine. A motility study in post-dependent rats. Neuropharmacology 22:1193-1196
8. Beckman TR, Shi Q, Levine AS, Billington CJ (2009) Amygdalar opioids modulate hypothalamic melanocortin-induced anorexia. Physiol Behav 96:568-573
9. Bhargava HN, Gulati A (1990) Down-regulation of brain and spinal cord mu-opiate receptors in morphine tolerant-dependent rats. Eur J Neurosci 190:305-311
10. Bodnar RJ (2011) Endogenous opiates and behavior: 2010. Peptides 32:2522-2552
11. Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG (2000) Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408:720-723
12. Borgland SL, Connor M, Osborne PB, Furness JB, Christie MJ (2003) Opioid agonists have different efficacy profiles for G protein activation, rapid desensitization, and endocytosis of mu-opioid receptors. J Biol Chem 278:18776-18784
13. Brodsky M, Elliott K, Hynansky A, Inturrisi CE (1995) CNS levels of mu opioid receptor (MOR-1) mRNA during chronic treatment with morphine or naltrexone. Brain Res Bull 38:135-141
14. Castelli MP, Melis M, Mameli M, Fadda P, Diaz G, Gessa GL (1997) Chronic morphine and naltrexone fail to modify mu-opioid receptor mRNA levels in the rat brain. Brain Res Bull 45:149-153
15. Centers for Disease Control and Prevention (2012) CDC grand rounds: prescription drug overdoses - a U.S. epidemic. MMWR Morb Mortal Wkly Rep 61:10-13
16. Comer SD, Ashworth JB, Sullivan MA, Vosburg SK, Saccone PA, Foltin RW (2009) Relationship between rate of infusion and reinforcing strength of oxycodone in humans. J Opioid Manag 5:203-212
17. Contet C, Kieffer BL, Befort K (2004) Mu opioid receptor: a gateway to drug addiction. Curr Opin Neurobiol 14:370-378
18. Contet C, Filliol D, Matifas A, Kieffer BL (2008) Morphine-induced analgesic tolerance, locomotor sensitization and physical dependence do not require modification of mu opioid receptor, cdk5 and adenylate cyclase activity. Neuropharmacology 54:475-486
19. Dalley JW, Laane K, Pena Y, Theobald DEH, Everitt BJ, Robbins TW (2005) Attentional and motivational deficits in rats withdrawn from intravenous self-administration of cocaine or heroin. Psychopharmacology (Berl) 182:579-587
20. Delfs JM, Zhu Y, Druhan JP, Aston-Jones G (2000) Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature 403:430-434
21. D'Este L, Scontrini A, Casini A, Pontieri FE, Renda TG (2002) Heroin sensitization as mapped by c-Fos immunoreactivity in the rat striatum. Brain Res 933:144-149
22. Dhabhar FS, McEwen BS, Spencer RL (1997) Adaptation to prolonged or repeated stress - comparison between rat strains showing intrinsic differences in reactivity to acute stress. Neuroendocrinology 65:360-368
23. Diana M, Muntoni AL, Pistis M, Melis M, Gessa GL (1999) Lasting reduction in mesolimbic dopamine neuronal activity after morphine withdrawal. Eur J Neurosci 11:1037-1041
24. Djurendic-Brenesel M, Mimica-Dukic N, Piilija V, Tasic M (2010) Gender-related differences in the pharmacokinetics of opiates. Forensic Sci Int 194:28-33
25. Duttaroy A, Yoburn BC (1995) The effect of intrinsic efficacy on opioid tolerance. Anesthesiology 82:1226-1236
26. Eitan S, Bryant CD, Saliminejad N, Yang YC, Vojdani E, Keith D Jr, Polakiewicz R, Evans CJ (2003) Brain region-specific mechanisms for acute morphine-induced mitogen-activated protein kinase modulation and distinct patterns of activation during analgesic tolerance and locomotor sensitization. J Neurosci 23:8360-8369
27. Erdtmann-Vourlioti M, Mayer P, Linke R, Reiechert U, Hollt V (1999) Long-lasting sensitization towards morphine in motoric and limbic areas as determined by c-fos expression in rat brain. Mol Brain Res 72:1-16
28. Ford CP, Beckstead MJ, Williams JT (2007) Kappa opioid inhibition of somatodendritic dopamine inhibitory postsynaptic currents. J Neurophysiol 97:883-891
29. Garcia-Lecumberri C, Torres I, Martin S, Crespo JA, Miguens M, Nicanor C, Higuera-Matas A, Ambrosio E (2011) Strain differences in the dose-response relationship for morphine self-administration and impulsive choice between Lewis and Fischer 344 rats. J Psychopharmacol 25:783-791
30. Gellert VF, Holtzman SG (1978) Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions. J Pharmacol Exp Ther 205:536-546
31. Georges F, Le Moine C, Aston-Jones G (2006) No effect of morphine on ventral tegmental dopamine neurons during withdrawal. J Neurosci 26:5720-5726
32. Glass MJ, Billington CJ, Levine AS (1999) Opioids and food intake: distributed functional neural pathways? Neuropeptides 33:360-368
33. Goeldner C, Lutz PE, Darcq E, Halter T, Clesse D, Ouagazzal AM, Kieffer BL (2011) Impaired emotional-like behavior and serotonergic function during protracted abstinence from chronic morphine. Biol Psychiatry 69:236-244
34. Grigorakos L, Sakagianni K, Tsigou E, Apostolakos G, Nikolopoulos G, Veldekis D (2010) Outcome of acute heroin overdose requiring intensive care unit admission. J Opioid Manag 6:227-231
35. Haertzen CA, Hooks NT (1969) Changes in personality and subjective experience associated with the chronic administration and withdrawal of opiates. J Nerv Men Dis 148:606-614
36. Harris GC, Aston-Jones G (2000) Augmented accumbal serotonin levels decrease the preference for a morphine associated environment during withdrawal. Neuropsychopharmacology 24:75-85
37. Havemann U, Kuschinsky K (1982) Review. Neurochemical aspects of the opioid-induced 'catatonia'. Neurochem Int 4:199-215
38. Inturrisi CE, Schultz M, Shin S, Umans JG, Angel L, Simon EJ (1983) Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci 33:773-776
39. Izumi J, Washizuka M, Hayashi-Kuwabara Y, Yoshinaga K, Tanaka Y, Ikeda Y, Kiuchi Y, Oguchi K (1997) Evidence for a depressive-like state induced by repeated saline injections in Fischer 344 rats. Pharmacol Biochem Behav 57:883-888
40. Jentsch JD, Taylor JR (1999) Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology (Berl) 146:373-390
41. Johnson SM, Fleming WW (1989) Mechanisms of cellular adaptive sensitivity changes: applications to opioid tolerance and dependence. Pharmacol Rev 41:435-488
42. Johnson SW, North RA (1992) Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12:483-488
43. Keith DE, Murray SR, Zaki PA, Chu PC, Lissin DV, Kang L, Evans C, von Zastrow M (1996) Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 271:19021-19024
44. Koob GF, Kreek MJ (2007) Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry 164:1149-1159
45. Koob GF, Le Moal M (2008) Addiction and the brain antireward system. Ann Rev Psychol 59:29-53
46. Kreek MJ (2008) Role of a functional human gene polymorphism in stress responsivity and addictions. Clin Pharmacol Ther 83:615-618
47. Kreek MJ, Koob GF (1998) Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend 51(1-2):23-47
48. Kreek MJ, LaForge KS (2007) Stress responsivity, addiction, and a functional variant of the human mu-opioid receptor gene. Mol Interv 7:74-78
49. Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA (2005) Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 57:1-26
50. Kreek MJ, Schlussman SD, Reed B, Zhang Y, Nielsen DA, Levran O, Zhou Y, Butelman ER (2009a) Bidirectional translational research: progress in understanding addictive diseases. Neuropharmacology 56(Suppl 1):32-43
51. Kreek MJ, Zhou Y, Butelman ER, Levran O (2009b) Opiate and cocaine addiction: from bench to clinic and back to the bench. Curr Opin Pharmacol 9:74-80
52. Kruzich PJ, Chen AC, Unterwald EM, Kreek MJ (2003) Subject-regulated dosing alters morphine self-administration behavior and morphine-stimulated [35S]GTPgammaS binding. Synapse 47:243-249
53. Kuribara H (1996) Effects of interdose interval on ambulatory sensitization to methamphetamine, cocaine and morphine in mice. Eur J Pharmacol 326:1-5
54. Langerman L, Piscoun B, Bansinath M, Shemesh Y, Turndorf H, Grant GJ (2001) Quantifiable dose-dependent withdrawal after morphine discontinuation in a rat model. Pharmacol Biochem Behav 68:1-6
55. Le Merrer J, Becker JA, Befort K, Kieffer BL (2009) Reward processing by the opioid system in the brain. Physiol Rev 89:1379-1412
56. Maher CE, Selley DE, Childers SR (2000) Relationship of mu opioid receptor binding to activation of G-proteins in specific rat brain regions. Biochem Pharmacol 59:1395-1401
57. Maher CE, Martin TJ, Childers SR (2005) Mechanisms of mu opioid receptor/G-protein desensitization in brain by chronic heroin administration. Life Sci 77:1140-1154
58. Martin S, Manzanares J, Corchero J, Garcia-Lecumberri C, Crespo JA, Fuentes JA, Ambrosio E (1999) Differential basal proenkephalin gene expression in dorsal striatum and nucleus accumbens, and vulnerability to morphine self-administration in Fischer 344 and Lewis rats. Brain Res 821:350-355
59. Martini L, Whistler JL (2007) The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence. Curr Opin Neurobiol 17:556-564
60. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P, Tzavara E, Hanoune J, Roques BP, Kieffer BL (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383:819-823
61. Mayo-Michelson L, Young GA (1992) Effects of chronic morphine administration and naloxone on EEG, EEG power spectra, and associated behavior in two inbred rat strains. Pharmacol Biochem Behav 42:815-821
62. Mirin SM, Meyer RE, McNamee HB (1976) Psychopathology and mood during heroin use: acute vs chronic effects. Arch Gen Psychiatry 33:1503-1508
63. Mucha RF, Kalant H (1981) Naloxone prevention of morphine LDR curve flattening associated with high-dose tolerance. Psychopharmacology (Berl) 75:132-133
64. Narita M, Shibasaki M, Nagumo Y, Narita M, Yajima Y, Suzuki T (2005) Implication of cyclin-dependent kinase 5 in the development of psychological dependence on and behavioral sensitization to morphine. J Neurochem 93:1463-1468
65. National Research Council (2010) Guide for the care and use of laboratory animals, 8th edn. The National Academies Press, Washington D.C
66. Negus SS, Rice KC (2009) Mechanisms of withdrawal-associated increases in heroin self-administration: pharmacologic modulation of heroin vs. food choice in heroin-dependent rhesus monkeys. Neuropsychopharmacology 34:899-911
67. Paolone G, Conversi D, Caprioli D, Bianco PD, Nencini P, Cabib S, Badiani A (2007) Modulatory effect of environmental context and drug history on heroin-induced psychomotor activity and fos protein expression in the rat brain. Neuropsychopharmacology 32:2611-2623
68. Paxinos G, Watson C (1986) The rat brain: in stereotaxic coordinates. Academic Press, New York
69. Picetti R, Caccavo JA, Ho A, Kreek MJ (2012) Dose escalation and dose preference in extended-access heroin self-administration in Lewis and Fischer rats. Psychopharmacology (Berl) 220:163-172
70. Piras AP, Zhou Y, Schlussman SD, Ho A, Kreek MJ (2010) Acute withdrawal from chronic escalating-dose binge cocaine administration alters kappa opioid receptor stimulation of [35S] guanosine 5′-O-[gamma-thio]triphosphate acid binding in the rat ventral tegmental area. Neuroscience 169:751-757
71. Ribeiro Do Couto B, Aguilar MA, Manzanedo C, Rodriguez-Arias M, Minarro J (2003) Reinstatement of morphine-induced conditioned place preference in mice by priming injections. Neural Plast 10:279-290
72. Roerig SC, Fujimoto JM, Lange DG (1987) Development of tolerance to respiratory depression in morphine- and etorphine-pellet-implanted mice. Brain Res 400:278-284
73. Schroeder JA, Niculescu M, Unterwald EM (2003) Cocaine alters mu but not delta or kappa opioid receptor-stimulated in situ [35S]GTPgammaS binding in rat brain. Synapse 47:26-32
74. Seip KM, Reed B, Ho A, Kreek MJ (2012) Measuring the incentive value of escalating doses of heroin in heroin-dependent Fischer rats during acute spontaneous withdrawal. Psychopharmacology (Berl) 219:59-72
75. Sim LJ, Selley DE, Dworkin SI, Childers SR (1996) Effects of chronic morphine administration on mu opioid receptor-stimulated [35S]GTPgammaS autoradiography in rat brain. J Neurosci 16:2684-2692
76. Sim-Selley LJ, Selley DE, Vogt LJ, Childers SR, Martin TJ (2000) Chronic heroin self-administration desensitizes mu-opioid receptor-activated G-proteins in specific regions of rat brain. J Neurosci 20:4555-4562
77. Spangler R, Zhou Y, Schlussman SD, Ho A, Kreek MJ (1997) Behavioral stereotypies induced by 'binge' cocaine administration are independent of drug-induced increases in corticosterone levels. Behav Brain Res 86:201-204
78. Sternini C, Spann M, Anton B, Keith DE Jr, Bunnett NW, Von Zastrow M, Evans C, Brecha NC (1996) Agonist-selective endocytosis of mu opioid receptor by neurons in vivo. Proc Natl Acad Sci USA 93:9241-9246
79. Szumlinski KK, Lominac KD, Frys KA, Middaugh LD (2005) Genetic variation in heroin-induced changes in behaviour: effects of B6 strain dose on conditioned reward and locomotor sensitization in 129-B6 hybrid mice. Genes Brain Behav 4:324-336
80. Taracha E, Chrapusta SJ, Lehner M, Skorzewska A, Maciejak P, Szyndler J, Plaznik A (2008) Morphine and methadone pre-exposures differently modify brain regional Fos protein expression and locomotor activity responses to morphine challenge in the rat. Drug Alcohol Depend 97:21-32
81. Tejada HA, Shippenberg TS, Henriksson R (2012) The dynorphin/kappa-opioid receptor system and its role in psychiatric disorders. Cell Mol Life Sci 69:857-896
82. Ulibarri I, Garcia-Sevilla JA, Ugedo L (1987) Modulation of brain alpha 2-adrenoceptor and mu-opioid receptor densities during morphine dependence and spontaneous withdrawal in rats. Naunyn Schmiedebergs Arch Pharmacol 336:530-537
83. Unterwald EM, Knapp C, Zukin RS (1991) Neuroanatomical localization of kappa 1 and kappa 2 opioid receptors in rat and guinea pig brain. Brain Res 562:57-65
84. Unterwald EM, Ho A, Rubenfeld JM, Kreek MJ (1994) Time course of the development of behavioral sensitization and dopamine receptor up-regulation during binge cocaine administration. J Pharmacol Exp Ther 270:1387-1396
85. Unterwald EM, Anton B, To T, Lam H, Evans CJ (1998) Quantitative immunolocalization of mu opioid receptors: regulation by naltrexone. Neuroscience 85:897-905
86. Vanderschuren LJ, Tjon GH, Nestby P, Mulder AH, Schoffelmeer AN, De Vries TJ (1997) Morphine-induced long-term sensitization to the locomotor effects of morphine and amphetamine depends on the temporal pattern of the pretreatment regimen. Psychopharmacology (Berl) 131:115-122
87. Warner-Smith M, Darke S, Lynskey M, Hall W (2001) Heroin overdose: causes and consequences. Addiction 96:1113-1125
88. Weber RJ, Gomez-Flores R, Smith JE, Martin TJ (2004) Immune, neuroendocrine, and somatic alterations in animal models of human heroin abuse. J Neuroimmunol 147:134-137
89. Werling LL, McMahon PN, Cox BM (1989) Selective changes in mu opioid receptor properties induced by chronic morphine exposure. Proc Natl Acad Sci USA 86:6393-6397
90. Winstanley CA, Olausson P, Taylor JR, Jentsch JD (2010) Insight into the relationship between impulsivity and substance abuse from studies using animal models. Alcohol Clin Exp Res 34:1306-1318
91. Zhang Y, Landthaler M, Schlussman SD, Yuferov V, Ho A, Tuschl T, Kreek MJ (2009) Mu opioid receptor knockdown in the substantia nigra/ventral tegmental area by synthetic small interfering RNA blocks the rewarding and locomotor effects of heroin. Neuroscience 158:474-483
92. Zhou Y, Bendor J, Hofmann L, Randesi M, Ho A, Kreek MJ (2006) Mu opioid receptor and orexin/hypocretin mRNA levels in the lateral hypothalamus and striatum are enhanced by morphine withdrawal. J Endocrinol 191:137-145
93. Zhou Y, Leri F, Cummins E, Hoeschele M, Kreek MJ (2008) Involvement of arginine vasopressin and V1b receptor in heroin withdrawal and heroin seeking precipitated by stress and by heroin. Neuropsychopharmacology 33:226-236
94. Zukin RS, Eghbali M, Olive D, Unterwald EM, Tempel A (1988) Characterization and visualization of rat and guinea pig brain kappa opioid receptors: evidence for kappa 1 and kappa 2 opioid receptors. Proc Natl Acad Sci USA 85:4061-4065